Avacta has covid-19 and cancer sewn up11 Aug 2020 10:05
There's an affirmer for everything!
Covid-19:
Waste water detection
Rapid test
Hospital high throughput test
Blocking therapies
Cancer:
Developing the next generation of cancer therapies
pre|CISION™ technology
Avacta’s proprietary pre|CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAPa) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues. The pre|CISION™ substrate can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments is improved.
Basically removes side effects of chemo